Breiter Capital Management Inc. Reduces Stock Position in Amgen, Inc. (NASDAQ:AMGN)

Share on StockTwits

Breiter Capital Management Inc. reduced its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 5,926 shares of the medical research company’s stock after selling 254 shares during the period. Amgen comprises 1.5% of Breiter Capital Management Inc.’s investment portfolio, making the stock its 17th largest position. Breiter Capital Management Inc.’s holdings in Amgen were worth $1,429,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of AMGN. Savior LLC purchased a new stake in Amgen in the fourth quarter worth about $34,000. Belmont Capital LLC purchased a new stake in Amgen in the fourth quarter worth about $36,000. Balentine LLC lifted its holdings in Amgen by 36.1% in the third quarter. Balentine LLC now owns 181 shares of the medical research company’s stock worth $35,000 after buying an additional 48 shares during the period. Barnett & Company Inc. lifted its holdings in Amgen by 4,725.0% in the fourth quarter. Barnett & Company Inc. now owns 193 shares of the medical research company’s stock worth $47,000 after buying an additional 189 shares during the period. Finally, Atwater Malick LLC purchased a new stake in Amgen in the third quarter worth about $39,000. Institutional investors own 76.78% of the company’s stock.

Several brokerages have commented on AMGN. SunTrust Banks began coverage on shares of Amgen in a report on Tuesday, November 12th. They issued a “buy” rating and a $256.00 price objective for the company. Mizuho restated a “hold” rating and issued a $212.00 price objective on shares of Amgen in a report on Sunday, September 29th. Raymond James assumed coverage on shares of Amgen in a research note on Monday, December 23rd. They set a “market perform” rating for the company. Morgan Stanley decreased their target price on shares of Amgen from $280.00 to $277.00 and set an “overweight” rating for the company in a research note on Friday, January 17th. Finally, UBS Group raised their target price on shares of Amgen from $194.00 to $238.00 and gave the company a “neutral” rating in a research note on Wednesday. Twelve investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $240.11.

Shares of NASDAQ AMGN opened at $235.04 on Friday. Amgen, Inc. has a fifty-two week low of $166.30 and a fifty-two week high of $244.99. The company has a 50 day simple moving average of $239.17 and a two-hundred day simple moving average of $210.94. The company has a market capitalization of $140.67 billion, a price-to-earnings ratio of 18.04, a P/E/G ratio of 2.05 and a beta of 1.11. The company has a debt-to-equity ratio of 2.54, a quick ratio of 2.59 and a current ratio of 2.89.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, October 29th. The medical research company reported $3.66 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.53 by $0.13. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.63 billion. Amgen had a net margin of 34.48% and a return on equity of 80.26%. The business’s revenue for the quarter was down 2.8% on a year-over-year basis. During the same quarter last year, the firm earned $3.69 earnings per share. On average, analysts forecast that Amgen, Inc. will post 14.64 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 14th will be given a dividend of $1.60 per share. The ex-dividend date is Thursday, February 13th. This represents a $6.40 annualized dividend and a dividend yield of 2.72%. This is an increase from Amgen’s previous quarterly dividend of $1.45. Amgen’s dividend payout ratio (DPR) is 40.28%.

In related news, CFO David W. Meline sold 8,737 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $234.36, for a total transaction of $2,047,603.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $215.45, for a total transaction of $91,566.25. Following the sale, the director now directly owns 5,413 shares of the company’s stock, valued at approximately $1,166,230.85. The disclosure for this sale can be found here. Insiders have sold 18,162 shares of company stock valued at $4,214,030 in the last three months. 0.25% of the stock is owned by insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Story: Liquidity

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

GAM Holding AG Has $316,000 Stake in Fidelity National Financial Inc
GAM Holding AG Has $316,000 Stake in Fidelity National Financial Inc
GAM Holding AG Makes New Investment in Funko Inc
GAM Holding AG Makes New Investment in Funko Inc
GAM Holding AG Trims Position in Constellation Brands, Inc.
GAM Holding AG Trims Position in Constellation Brands, Inc.
GAM Holding AG Sells 5,136 Shares of HCA Healthcare Inc
GAM Holding AG Sells 5,136 Shares of HCA Healthcare Inc
GAM Holding AG Makes New $332,000 Investment in Nordson Co.
GAM Holding AG Makes New $332,000 Investment in Nordson Co.
GAM Holding AG Has $337,000 Stock Holdings in Pentair PLC
GAM Holding AG Has $337,000 Stock Holdings in Pentair PLC


© 2006-2020 Ticker Report